Veracyte Inc (VCYT)

Dec 5, 2024, 4:05 PM EST - 6 weeks ago

Veracyte's Decipher Prostate Test Is Now the Only Gene Expression Test Recommended in NCCN® Prostate Cancer Guidelines

Nov 6, 2024, 10:49 PM EST - 2 months ago

Veracyte, Inc. (VCYT) Q3 2024 Earnings Call Transcript

Nov 6, 2024, 4:05 PM EST - 2 months ago

Veracyte Announces Third Quarter 2024 Financial Results

Oct 30, 2024, 5:00 PM EDT - 2 months ago

Veracyte to Participate in Upcoming Investor Conferences

Oct 16, 2024, 6:43 PM EDT - 3 months ago

Veracyte to Release Third Quarter 2024 Financial Results on November 6, 2024

Sep 15, 2024, 8:45 AM EDT - 4 months ago

New Data Presented at ESMO 2024 Show that Veracyte's Decipher Prostate Test Predicts Chemotherapy Benefit in Patients with Metastatic Prostate Cancer

Sep 4, 2024, 4:05 PM EDT - 4 months ago

Veracyte Appoints Brent Shafer and Tom Miller, Ph.D., to Its Board of Directors

Aug 26, 2024, 5:30 PM EDT - 5 months ago

Veracyte to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference

Aug 26, 2024, 9:00 AM EDT - 5 months ago

Veracyte Named a Greater Bay Area Top Workplace by the San Francisco Chronicle

Aug 7, 2024, 2:08 PM EDT - 5 months ago

Diagnostic Tests Maker Veracyte's Q2 Is 'All-Around Very Good Quarter': Analysts Maintain Bullish View

Aug 6, 2024, 10:17 PM EDT - 5 months ago

Veracyte, Inc. (VCYT) Q2 2024 Earnings Call Transcript

Aug 6, 2024, 4:05 PM EDT - 5 months ago

Veracyte Announces Second Quarter 2024 Financial Results

Jul 17, 2024, 5:00 PM EDT - 6 months ago

Veracyte to Release Second Quarter 2024 Financial Results on August 6, 2024

Jun 3, 2024, 4:05 PM EDT - 8 months ago

Veracyte Announces that New Afirma GRID Data Suggest Prognostic Ability of Molecular Testing for Thyroid Tumors

May 22, 2024, 4:05 PM EDT - 8 months ago

Veracyte Announces Multiple Afirma GRID Presentations at ENDO 2024, Previewing the Future of Molecular Testing in Thyroid Nodules and Cancer

May 7, 2024, 4:05 PM EDT - 9 months ago

Veracyte Announces First Quarter 2024 Financial Results

May 6, 2024, 4:05 PM EDT - 9 months ago

14 Studies Presented at AUA 2024 Show Decipher Tests' Ability to Help Personalize Care for Prostate and Bladder Cancer Patients and Advance Disease Understanding

Apr 22, 2024, 5:00 PM EDT - 9 months ago

Veracyte to Release First Quarter 2024 Financial Results on May 7, 2024

Apr 22, 2024, 8:30 AM EDT - 9 months ago

New Study Shows Veracyte's Decipher Prostate Test is Prognostic for Prostate Cancer Progression Among Patients Undergoing Active Surveillance

Apr 16, 2024, 8:30 AM EDT - 9 months ago

Veracyte Announces that Nine Studies Reinforcing the Value of Decipher Prostate and Decipher Bladder Testing Will Be Presented at AUA 2024

Feb 27, 2024, 5:55 PM EST - 11 months ago

Veracyte's Decipher Prostate Test Receives Highest Evidence-Level Rating Among Molecular Tests in Updated Prostate Cancer NCCN Guidelines

Feb 22, 2024, 9:24 PM EST - 11 months ago

Veracyte, Inc. (VCYT) Q4 2023 Earnings Call Transcript

Feb 22, 2024, 4:05 PM EST - 11 months ago

Veracyte Announces Fourth Quarter and Full-Year 2023 Financial Results

Feb 21, 2024, 5:00 PM EST - 11 months ago

Veracyte to Participate in the Raymond James 45th Annual Institutional Investors Conference

Feb 8, 2024, 8:00 AM EST - 1 year ago

Veracyte to Release Fourth Quarter and Full-Year 2023 Financial Results on February 22, 2024

Feb 6, 2024, 8:15 AM EST - 1 year ago

Veracyte Completes Acquisition of C2i Genomics

Jan 8, 2024, 8:00 AM EST - 1 year ago

Veracyte Announces Preliminary Full-Year 2023 Results, Acquisition of C2i Genomics to Add Minimal Residual Disease Capabilities to Its Novel Diagnostics Platform

Dec 12, 2023, 4:30 PM EST - 1 year ago

Veracyte to Participate in the 42nd Annual J.P. Morgan Healthcare Conference

Dec 1, 2023, 4:05 PM EST - 1 year ago

Real-World Data Presented at SUO 2023 Show that Veracyte's Decipher Genomic Classifier Identifies Patients Whose Prostate Cancer is Likely to Progress

Nov 29, 2023, 8:30 AM EST - 1 year ago

Clinical Validation Data Published in CHEST Demonstrate that Veracyte's Percepta Nasal Swab Test Improves Lung Cancer Risk Assessment for Patients with Lung Nodules

Nov 22, 2023, 8:30 AM EST - 1 year ago

Veracyte Announces Seven Posters Highlighting Clinical Value of Decipher Prostate Genomic Testing To be Presented at SUO 2023

Nov 7, 2023, 8:57 PM EST - 1 year ago

Veracyte, Inc. (VCYT) Q3 2023 Earnings Call Transcript

Nov 7, 2023, 4:05 PM EST - 1 year ago

Veracyte Announces Third Quarter 2023 Financial Results

Nov 7, 2023, 4:00 PM EST - 1 year ago

Veracyte Announces In Vitro Diagnostic Agreement with Illumina to Broaden Availability of Its Tests for Patients Globally

ILMN

Nov 2, 2023, 8:15 AM EDT - 1 year ago

Veracyte to Participate in the Stephens Annual Investment Conference

Oct 27, 2023, 8:30 AM EDT - 1 year ago

Veracyte Announces SITC 2023 Presentations Offering New Insight into Immuno-oncology Drug Development

Oct 17, 2023, 8:15 AM EDT - 1 year ago

Veracyte to Release Third Quarter 2023 Financial Results on November 7, 2023

Oct 12, 2023, 9:00 AM EDT - 1 year ago

New Data Presented at CHEST 2023 Demonstrate the Clinical Utility of Veracyte's Envisia Genomic Classifier for Patients with Interstitial Lung Disease

Oct 4, 2023, 4:05 PM EDT - 1 year ago

New Data from Phase 3 Trial Further Validate Prognostic Value of Veracyte's Decipher Prostate Genomic Classifier

Sep 28, 2023, 4:05 PM EDT - 1 year ago

New Data Presented at the 2023 ATA Annual Meeting Demonstrate that Veracyte's Afirma-Based Testing Can Uncover Key Molecular Hallmarks of Thyroid Cancer

Sep 28, 2023, 8:15 AM EDT - 1 year ago

Veracyte Announces Multiple Studies Reinforcing the Value of Decipher Prostate Testing Will Be Presented at ASTRO 2023

Sep 27, 2023, 9:00 AM EDT - 1 year ago

Veracyte Names Phillip G. Febbo, M.D.

Sep 21, 2023, 4:05 PM EDT - 1 year ago

Veracyte Announces Novel Afirma-Based Findings that Advance Molecular Understanding of Thyroid Cancer to Be Presented at the 2023 ATA Annual Meeting

Sep 7, 2023, 4:05 PM EDT - 1 year ago

Veracyte Names Marie-Claire Taine, Ph.D., as General Manager of Its IVD Business Unit To Advance Global Expansion of the Company's Tests

Sep 6, 2023, 8:15 AM EDT - 1 year ago

Veracyte and Gustave Roussy Announce Collaboration to Help Biopharmaceutical Companies Accelerate Development of Novel Cancer Therapies

Aug 29, 2023, 8:15 AM EDT - 1 year ago

Veracyte to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference

Aug 22, 2023, 8:15 AM EDT - 1 year ago

Veracyte Announces that Findings Published in JCO Precision Oncology Suggest Potential of Decipher GRID-Derived Gene Signatures to Predict Treatment Response in Recurrent Prostate Cancer

Aug 15, 2023, 4:15 PM EDT - 1 year ago

Veracyte Earns Top Workplace Awards in the San Francisco Bay Area and San Diego

Aug 8, 2023, 4:05 PM EDT - 1 year ago

Veracyte Announces Second Quarter 2023 Financial Results

Aug 1, 2023, 8:15 AM EDT - 1 year ago

Study Published in JNCI Cancer Spectrum Demonstrates Real-World Utility of Veracyte's Decipher Prostate Genomic Classifier in Prostate Cancer Treatment